Article

Emergence of Multiclass Drug-Resistance in HIV-2 in Antiretroviral-Treated Individuals in Senegal: Implications for HIV-2 Treatment in Resouce-Limited West Africa

Department of Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Clinical Infectious Diseases (Impact Factor: 9.42). 03/2009; 48(4):476-83. DOI: 10.1086/596504
Source: PubMed

ABSTRACT The efficacy of various antiretroviral (ARV) therapy regimens for human immunodeficiency virus type 2 (HIV-2) infection remains unclear. HIV-2 is intrinsically resistant to the nonnucleoside reverse-transcriptase inhibitors and to enfuvirtide and may also be less susceptible than HIV-1 to some protease inhibitors (PIs). However, the mutations in HIV-2 that confer ARV resistance are not well characterized.
Twenty-three patients were studied as part of an ongoing prospective longitudinal cohort study of ARV therapy for HIV-2 infection in Senegal. Patients were treated with nucleoside reverse-transcriptase inhibitor (NRTI)- and PI (indinavir)-based regimens. HIV-2 pol genes from these patients were genotyped, and the mutations predictive of resistance in HIV-2 were assessed. Correlates of ARV resistance were analyzed.
Multiclass drug-resistance mutations (NRTI and PI) were detected in strains in 30% of patients; 52% had evidence of resistance to at least 1 ARV class. The reverse-transcriptase mutations M184V and K65R, which confer high-level resistance to lamivudine and emtricitabine in HIV-2, were found in strains from 43% and 9% of patients, respectively. The Q151M mutation, which confers multinucleoside resistance in HIV-2, emerged in strains from 9% of patients. HIV-1-associated thymidine analogue mutations (M41L, D67N, K70R, L210W, and T215Y/F) were not observed, with the exception of K70R, which was present together with K65R and Q151M in a strain from 1 patient. Eight patients had HIV-2 with PI mutations associated with indinavir resistance, including K7R, I54M, V62A, I82F, L90M, L99F; 4 patients had strains with multiple PI resistance-associated mutations. The duration of ARV therapy was positively associated with the development of drug resistance (P = .02). Nine (82%) of 11 patients with HIV-2 with no [corrected] detectable ARV resistance had undetectable plasma HIV-2 RNA loads (<1.4 log(10) copies/mL), compared with 3 (25%) of 12 patients with HIV-2 with detectable ARV resistance (P = .009). Patients with ARV-resistant virus had higher plasma HIV-2 RNA loads, compared with those with non-ARV-resistant virus (median, 1.7 log(10) copies/mL [range, <1.4 to 2.6 log(10) copies/mL] vs. <1.4 log(10) copies/mL [range, <1.4 to 1.6 log(10) copies/mL]; P = .003).
HIV-2-infected individuals treated with ARV therapy in Senegal commonly have HIV-2 mutations consistent with multiclass drug resistance. Additional clinical studies are required to improve the efficacy of primary and salvage treatment regimens for treating HIV-2 infection.

Download full-text

Full-text

Available from: James I Mullins, Jul 18, 2014
0 Followers
 · 
99 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV-2 contributes approximately a third to the prevalence of HIV in West Africa and is present in significant amounts in several low-income countries outside of West Africa with historical ties to Portugal. It complicates HIV diagnosis, requiring more expensive and technically demanding testing algorithms. Natural polymorphisms and patterns in the development of resistance to antiretrovirals are reviewed, along with their implications for antiretroviral therapy. Nonnucleoside reverse transcriptase inhibitors, crucial in standard first-line regimens for HIV-1 in many low-income settings, have no effect on HIV-2. Nucleoside analogues alone are not sufficiently potent enough to achieve durable virologic control. Some protease inhibitors, in particular those without ritonavir boosting, are not sufficiently effective against HIV-2. Following review of the available evidence and taking the structure and challenges of antiretroviral care in West Africa into consideration, the authors make recommendations and highlight the needs of special populations.
    AIDS research and treatment 01/2011; 2011:463704. DOI:10.1155/2011/463704
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This doctoral thesis includes four projects. The first project explored the role of innate HIV genetic polymorphisms in drug-selected mutations. By means of drug selection experiments, we comparatively evaluated emergent mutations in protease and reverse transcriptase in HIV-1 and HIV-2 subtypes. Genotypic and phenotypic analyses were used to determine time to appearance of resistance mutations and the levels of drug resistance, respectively. Natural polymorphisms in HIV-2 seemed to facilitate selection of protease inhibitor (PI) resistance: The acquisition of the I54M, I84V, L90M and L99F mutations resulted in multi-PI-resistant viruses. Nucleoside reverse transcriptase inhibitor (NRTI) combinations preferentially selected for the K65R mutation in HIV-1 subtype C, while in HIV-1 subtype B, and HIV-2 cultures favored the development of M184I. The K65R mutation was not detected in HIV-2 selections. These results underscore potential differences in emergent drug resistance pathways in HIV-1 and HIV-2 and the role that innate polymorphisms may have in dictating antiretroviral resistance pathways. In the second project, we studied the relationship between mutations in the RNase H domain on viral susceptibility to nucleoside analogues. Our results showed that although some mutations were observed in the connection domain, the presence of the L74V and M184V mutations was the most significant determinant of phenotypic resistance to ZDV in patients with thymidine analog-associated mutations. The third project performed a near full-length genomic analysis of a novel HIV-1 recombinant involving subtypes A1 and C in Quebec. The fourth project evaluated the genetic diversity of an HIV-1 isolate that was referred to us as a suspected case of superinfection. We evaluated this isolate's sequences from different time points and determined that the sequence was a unique A1/C inter-subtype recombinant at baseline and not a case of superinfection. We concluded that discrepancies of online tools for subtype designation of HIV may lead to false designation of dual infection and/or superinfection. Cette thèse de doctorat comprend 4 projets. Le premier explore le rôle du polymorphisme génétique du VIH dans la sélection des mutations de résistance. Au cours des tests de sélection, nous avons évalué comparativement le délai dans lequel les mutations de résistance émergent dans la protéase et la transcriptase inverse des sous-types de VIH-1 et de VIH-2. Des analyses génotypiques et phénotypiques ont été utilisées pour déterminer le délai d'émergence et le niveau de résistance des mutations, respectivement. Le polymorphisme naturel du VIH-2 semble faciliter la sélection des mutations de résistance aux inhibiteurs de protéase (IPs). L'acquisition des mutations de résistance I54M, I84V, L90M et L99F entraine une résistance croisée à plusieurs IPs. Les combinaisons d'inhibiteurs nucléosidiques de la transcriptase inverse (INTI) sélectionnent préférentiellement la mutation K65R chez le VIH-1 de sous-type C alors que les cultures du sous-type B et le VIH-2 favorisent le développement de M184I. La mutation K65R n'a jamais été détectée dans les sélections de VIH-2. Ces résultats mettent en évidence des différences dans les mécanismes de résistance du VIH-1 et du VIH-2 et le rôle que certain polymorphisme jouent dans les voies génétiques de résistance. Dans le second projet, nous avons étudié la relation existante entre le polymorphisme dans la RNAse H et la sensibilité aux analogues nucléosidiques. Nos résultats montrent que bien que certaines mutations soient observées dans le domaine de connection, la présence des mutations L74V et M184V était le facteur déterminant de la résistance phénotypique à la ZDV chez les patients avec des mutations TAMs (Thymidine Analogues Mutations). Le troisième projet a permi de caractériser le génome d'un nouveau recombinant de VIH-1 impliquant les sous-types A1 et C au Quebec. Le quatrième projet a évalué la diversité génétique d'une souche de VIH-1 qui nous a été référé comme un cas de super-infection. L'analyse des séquences à différentes périodes nous a montré qu'il s'agit bien d'un recombinant unique A1/C et non d'une super infection. Nous avons conclu que les discordances entre les outils en ligne pour la détermination des sous-types peuvent être la cause d'une mauvaise désignation des sous-types et/ou des super-infections.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Scientists have long established that the human immunodeficiency virus type 1 (HIV-1) is the causative agent of the acquired immunodeficiency syndrome (AIDS) (4, 30, 48). ...
    Antimicrobial Agents and Chemotherapy 06/2009; 53(9):3611-9. DOI:10.1128/AAC.00154-09 · 4.45 Impact Factor